(Bloomberg) -- Latigo Biotherapeutics Inc. filed for an initial public offering, joining a growing list of biotechnology firms considering going public as soon as this quarter.Most Read from BloombergFCC Near Rulings Against Disney Over ‘The View,’ TV LicensesChipmakers Bounce After Plunge to Bear-Market Edge: Markets WrapGoogle Gemini Launch Delayed as Tech Falls Short of Internal GoalsChina’s Moonshot Unveils AI Model That Narrows Gap With US FirmsThailand Scraps Plan to End Visa-Free Entry fo
Notícias
Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.
325last 24h
2136last 7d
376● bullish (7d)
188● bearish (7d)
204publishers
Bloomberg26d agoneutral
Blue Owl-Backed Latigo Files for IPO, Adding to Biotech Pipeline